Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Koenig – page 120

1 643 clinical trials in Bad Koenig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Koenig at a glance
1 643
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 643 trials in Bad Koenig

Open in trial search

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Tacrolimus Formulations for Preventing Kidney Transplant Rejection in Adults

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MBS2320
  • Sponsor:Modern Biosciences Limited

Malignant melanoma

Not recruiting

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Dyspepsia+1

Not recruiting

Study on Juniper Berry Oil for Digestive Issues like Cramps, Gas, and Bloating in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Juniper Berry Oil
  • Sponsor:CGBS GbR

Deafness neurosensory

Not recruiting

Study on ACOU085 to Prevent Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ACOU085
  • Sponsor:Acousia Therapeutics GmbH

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Long-term Safety Study of Mavacamten for Adults with Hypertrophic Cardiomyopathy from Previous Trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Koenig

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. These studies are investigating innovative approaches for patients undergoing regular dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

Current research aims to evaluate new therapeutic interventions targeting C-reactive protein levels, a key marker of inflammation in cardiovascular disease, potentially offering new hope for dialysis patients dealing with cardiovascular complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.